Literature DB >> 16011334

An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.

Xiangshu Xiao1, Mark Cushman.   

Abstract

Camptothecin (CPT), a cytotoxic natural alkaloid isolated from Camptotheca acuminata, and its derivatives represent an important class of cancer chemotherapeutic drugs that act by inhibiting topoisomerase I (top1). The mechanism of top1 inhibition by CPT has been determined by X-ray crystallography. Biochemical studies carried out both in vitro and in vivo indicated that CPT has strict DNA sequence preference for -1 T and strong preference for +1 G at the cleavage site. To understand the molecular determinants for the CPT binding orientation and DNA sequence selectivity, we present a quantum mechanics calculation where only pi-pi stacking interactions were included to shed some light on the mechanism of this sequence selectivity. This ab initio calculation can not only reproduce the experimental binding orientation of CPT at the cleavage site but also shows very good correlation between the binding energy for different sequences and the observed frequency of CPT-stabilized sites in the SV40 viral genome. Therefore, it can be concluded that hydrogen bonding of the ligand to the surrounding amino acid residues of the protein is of minor significance. The present method should be applicable to other polycyclic top1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011334      PMCID: PMC2526349          DOI: 10.1021/ja042485n

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  12 in total

1.  Structure, energetics, and dynamics of the nucleic Acid base pairs: nonempirical ab initio calculations.

Authors:  P Hobza; J Sponer
Journal:  Chem Rev       Date:  1999-11-10       Impact factor: 60.622

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Authors:  C Pondarré; D Strumberg; A Fujimori; R Torres-León; Y Pommier
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

4.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.

Authors:  M R Redinbo; L Stewart; P Kuhn; J J Champoux; W G Hol
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

5.  An optimized potential function for the calculation of nucleic acid interaction energies I. base stacking.

Authors:  R L Ornstein; R Rein
Journal:  Biopolymers       Date:  1978-10       Impact factor: 2.505

6.  A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.

Authors:  J E Kerrigan; D S Pilch
Journal:  Biochemistry       Date:  2001-08-21       Impact factor: 3.162

7.  Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin.

Authors:  C Jaxel; G Capranico; D Kerrigan; K W Kohn; Y Pommier
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

8.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

Review 9.  Camptothecin: current perspectives.

Authors:  Craig J Thomas; Nicolas J Rahier; Sidney M Hecht
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

10.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.

Authors:  Y Fan; J N Weinstein; K W Kohn; L M Shi; Y Pommier
Journal:  J Med Chem       Date:  1998-06-18       Impact factor: 7.446

View more
  12 in total

1.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

2.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Authors:  Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

4.  Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.

Authors:  Evgeny Kiselev; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

5.  The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.

Authors:  Maris A Cinelli; Andrew E Morrell; Thomas S Dexheimer; Keli Agama; Surbhi Agrawal; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2010-06-20       Impact factor: 3.641

6.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

7.  Total synthesis and biological evaluation of 22-hydroxyacuminatine.

Authors:  Xiangshu Xiao; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

8.  The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.

Authors:  Yunlong Song; Mark Cushman
Journal:  J Phys Chem B       Date:  2008-07-18       Impact factor: 2.991

9.  Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.

Authors:  Daniel E Beck; P V Narasimha Reddy; Wei Lv; Monica Abdelmalak; Gabrielle S Tender; Sophia Lopez; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-12       Impact factor: 7.446

10.  The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.

Authors:  Paola Fiorani; Giovanni Chillemi; Carmen Losasso; Silvia Castelli; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2006-09-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.